Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million

Reuters03-24

<a href="https://laohu8.com/S/AARD">Aardvark Therapeutics</a> Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million

Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.
Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.
R&D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&A expense more than doubled to USD 4.4 million.
Net loss was USD 57.6 million and net loss per share was USD 2.93 for FY 2025.
Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9677034) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621608125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621608125","market":"us","top_or_hot":-1,"title":"Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Q4 net loss rises 100% to USD 18 million on R&amp;D expense up 77% to USD 14 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.\n        </li>\n<li>\n          Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.\n        </li>\n<li>\n          R&amp;D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&amp;A expense more than doubled to USD 4.4 million.\n        </li>\n<li>\n          Net loss was USD 57.6 million and net loss per share was USD 2.93 for FY 2025.\n        </li>\n<li>\n          Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9677034) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> Q4 net loss rises 100% to USD 18 million on R&amp;D expense up 77% to USD 14 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.\n        </li>\n<li>\n          Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.\n        </li>\n<li>\n          R&amp;D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&amp;A expense more than doubled to USD 4.4 million.\n        </li>\n<li>\n          Net loss was USD 57.6 million and net loss per share was USD 2.93 for FY 2025.\n        </li>\n<li>\n          Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9677034) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8c54RZ:1","article_id":"2621608125","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621608125","pubTimestamp":1774296439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.R&D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&A expense more than doubled to USD 4.4 million.Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in Q2 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"Aardvark Therapeutics第四季度净亏损上升100%至1800万美元，研发费用上升77%至1400万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":0.9,"NDAQ":0.9},"content_text":"Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million\n    \n\n\n          Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.\n        \n\n          Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.\n        \n\n          R&D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&A expense more than doubled to USD 4.4 million.\n        \n\n          Net loss was USD 57.6 million and net loss per share was USD 2.93 for FY 2025.\n        \n\n          Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in Q2 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231605PRIMZONEFULLFEED9677034) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621608125","isCrawlerRequest":true}